DelveInsight’s, “Schizophrenia Pipeline Insight 2023” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Schizophrenia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Schizophrenia Pipeline Report

• DelveInsight’s Schizophrenia pipeline report depicts a robust space with 70+ active players working to develop 70+ pipeline therapies for Schizophrenia treatment.
• The leading companies working in the Schizophrenia Market include Otsuka Pharmaceutical Development & Commercialization, Inc., Gedeon Richter Ltd., Neurocrine Bioscience, Takeda Pharmaceutical Company, Memory Pharmaceuticals, Hoffmann-La Roche, Neurocrine Biosciences, H. Lundbeck, Organon and Co, Meiji Seika Pharma Co., Ltd., SK Life Science, Inc., Novartis Pharmaceuticals, Vanda Pharmaceuticals, Alkermes, Inc., Solvay Pharmaceuticals, Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, SyneuRx International (Taiwan) Corp, BioXcel Therapeutics Inc., Cognitive Research Corporation, Amarex Clinical Research, Forum Pharmaceuticals Inc., Amneal Pharmaceuticals, LLC, Accutest Research Laboratories (I) Pvt. Ltd., Eli Lilly and Company, Johnson & Johnson Pharmaceutical Research & Development, L.L.C, Janssen LP, Delpor Inc., Cerevel Therapeutics, LLC, Zogenix, Inc., Reviva Pharmaceuticals, Alkermes, Inc., Karuna Therapeutics, and others.
• Promising Schizophrenia Pipeline Therapies in the various stages of development include Brexpiprazole (OPC-34712), Cariprazine, Xanomeline and Trospium Chloride Capsules, Aripiprazole IM Depot, CTP-692, Aripiprazole, OPC-34712FUM/ Brexpiprazole fumarate, Luvadaxistat, and others.
• February 2023: BioXcel Therapeutics Inc. announced a study of phase 1 clinical trials for Sublingual film containing BXCL501 (Dexmedetomidine). This is a two-stage adaptive Phase Ib trial design, that will identify two doses (lowest dose with clinical benefit and highest safe dose) in a first stage and better evaluate safety, tolerability and variability of effect in the second stage.
• June 2023: Sumitomo Pharma America Inc. announced a study of phase 1 clinical trials for SEP-363856. A Clinical Study to learn if SEP-363856 has physical dependence in adults with schizophrenia. This study will be held in approximately 6 study sites in the United States. It will be accepting male and female participants age 18 years to 65 years. Participation will be up to approximately 10 weeks.

 

Request a sample and discover the recent advances in Schizophrenia Treatment Drugs @ Schizophrenia Pipeline Report

 

In the Schizophrenia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Schizophrenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Schizophrenia Overview

Schizophrenia causes psychosis and is associated with considerable disability and may affect all areas of life including personal, family, social, educational, and occupational functioning. It is thought that an interaction between genes and a range of environmental factors may cause schizophrenia.

 

Find out more about Schizophrenia Treatment Drugs @ Drugs for Schizophrenia Treatment

 

Schizophrenia Emerging Drugs Profile

• Ulotaront: Otsuka Pharmaceutical
• Luvadaxistat: Takeda
• CY6463: Cyclerion Therapeutics
• AVP 786: Avanir Pharmaceuticals

 

Schizophrenia Pipeline Therapeutics Assessment

There are approx. 70+ key companies which are developing the Schizophrenia therapies. The Schizophrenia companies which have their Schizophrenia drug candidates in the most advanced stage, i.e. phase III include, Otsuka Pharmaceutical.

 

Learn more about the emerging Schizophrenia Pipeline Therapies @ Schizophrenia Clinical Trials Assessment

 

Scope of the Schizophrenia Pipeline Report

• Coverage- Global
• Schizophrenia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Schizophrenia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Schizophrenia Companies- Otsuka Pharmaceutical Development & Commercialization, Inc., Gedeon Richter Ltd., Neurocrine Bioscience, Takeda Pharmaceutical Company, Memory Pharmaceuticals, Hoffmann-La Roche, Neurocrine Biosciences, H. Lundbeck, Organon and Co, Meiji Seika Pharma Co., Ltd., SK Life Science, Inc., Novartis Pharmaceuticals, Vanda Pharmaceuticals, Alkermes, Inc., Solvay Pharmaceuticals, Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, SyneuRx International (Taiwan) Corp, BioXcel Therapeutics Inc., Cognitive Research Corporation, Amarex Clinical Research, Forum Pharmaceuticals Inc., Amneal Pharmaceuticals, LLC, Accutest Research Laboratories (I) Pvt. Ltd., Eli Lilly and Company, Johnson & Johnson Pharmaceutical Research & Development, L.L.C, Janssen LP, Delpor Inc., Cerevel Therapeutics, LLC, Zogenix, Inc., Reviva Pharmaceuticals, Alkermes, Inc., Karuna Therapeutics, and others.
• Schizophrenia Pipeline Therapies- Brexpiprazole (OPC-34712), Cariprazine, Xanomeline and Trospium Chloride Capsules, Aripiprazole IM Depot, CTP-692, Aripiprazole, OPC-34712FUM/ Brexpiprazole fumarate, Luvadaxistat, and others.

 

Dive deep into rich insights for new drugs for Schizophrenia treatment, Visit @ Schizophrenia Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Schizophrenia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Schizophrenia – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Ulotaront: Otsuka Pharmaceutical
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. Deudextromethorphan: Avanir Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. Luvadaxistat: Takeda
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I/II)
17. SP-624: Sirtsei Pharmaceuticals
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. CY6463: Cyclerion Therapeutics
21. Drug profiles in the detailed report…..
22. Preclinical and Discovery Stage Products
23. Psychiatric disorder therapies: Cardiff University/Takeda
24. Drug profiles in the detailed report…..
25. Inactive Products
26. Schizophrenia Key Companies
27. Schizophrenia Key Products
28. Schizophrenia – Unmet Needs
29. Schizophrenia – Market Drivers and Barriers
30. Schizophrenia – Future Perspectives and Conclusion
31. Schizophrenia Analyst Views
32. Schizophrenia Key Companies
33. Appendix

 

For further information on the Schizophrenia pipeline therapeutics, reach out to Schizophrenia Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking